NIAID

The 2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan (SIP), released this week by the U.S. Department of Health and Human Services, describes the priorities that HHS, in collaboration [Read more]

Pluristem Therapeutics on Dec. 6 announced a milestone in its development program for PLX-R18, which is being evaluated as a medical countermeasure in the treatment of the hematologic components of Acute Radiation [Read more]

National Institute of Allergy & Infectious Diseases (NIAID) has awarded new contracts under a Broad Agency Announcement (BAA) for Development of Therapeutic Products for Biodefense & Emerging Infectious Diseases. The BAA focuses [Read more]

A collaboration of research groups led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have published new research examining the association between Plasmodium infection and surviving an Ebola [Read more]

The National Institute of Allergy and Infectious Diseases (NIAID), Division of Clinical Research (DCR), rapidly deploys administrative and technical research support services and resources to conduct time sensitive, high priority collaborative clinical [Read more]

The National Institute of Allergy and Infectious Diseases (NIAID) has exercised a funding option with Soligenix, Inc. to advance preclinical development of OrbeShield, a radiation medical countermeasure. The 12-month option provides an additional [Read more]

Soligenix, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance the development of Soligenix’s heat stabilized ricin toxin vaccine, RiVax. The overall [Read more]

The National Institute of Allergy and Infectious Diseases (NIAID) has released a new Broad Agency Announcement (BAA) to support development of therapeutic products for use in post-event settings following the intentional release [Read more]

Soligenix, Inc. this week announced that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen. RiVax is [Read more]